In summary, we compared CD21, 32 and 35 markers on B and T cell population in MS patients and found that the fraction of CD32+ cells among CD4+ T cells and the fraction of CD21+ cell among CD8+ T cells are higher in MS patients than control subjects. Here, CR2 is linked to myeloid sarcoma.